Coherus BioSciences Statistics
Total Valuation
CHRS has a market cap or net worth of $118.24 million. The enterprise value is $301.18 million.
Important Dates
The last earnings date was Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CHRS has 115.92 million shares outstanding. The number of shares has increased by 21.95% in one year.
| Current Share Class | 115.92M |
| Shares Outstanding | 115.92M |
| Shares Change (YoY) | +21.95% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 4.42% |
| Owned by Institutions (%) | 57.45% |
| Float | 110.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.44 |
| Forward PS | 0.71 |
| PB Ratio | -0.64 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 236.48 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.94
| Current Ratio | 1.94 |
| Quick Ratio | 0.98 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.75 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -7.93% |
| Return on Invested Capital (ROIC) | -18.71% |
| Return on Capital Employed (ROCE) | -32.26% |
| Revenue Per Employee | $1.19M |
| Profits Per Employee | -$574,285 |
| Employee Count | 228 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 3.63 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.32% in the last 52 weeks. The beta is 1.01, so CHRS's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | -46.32% |
| 50-Day Moving Average | 0.96 |
| 200-Day Moving Average | 1.15 |
| Relative Strength Index (RSI) | 52.44 |
| Average Volume (20 Days) | 1,709,011 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CHRS had revenue of $272.25 million and -$130.94 million in losses. Loss per share was -$1.14.
| Revenue | 272.25M |
| Gross Profit | 153.48M |
| Operating Income | -72.02M |
| Pretax Income | -29.72M |
| Net Income | -130.94M |
| EBITDA | -66.93M |
| EBIT | -72.02M |
| Loss Per Share | -$1.14 |
Full Income StatementBalance Sheet
The company has $82.41 million in cash and $265.35 million in debt, giving a net cash position of -$182.94 million or -$1.58 per share.
| Cash & Cash Equivalents | 82.41M |
| Total Debt | 265.35M |
| Net Cash | -182.94M |
| Net Cash Per Share | -$1.58 |
| Equity (Book Value) | -183.47M |
| Book Value Per Share | -1.58 |
| Working Capital | 139.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $500,000 and capital expenditures -$192.54 million, giving a free cash flow of -$20.44 million.
| Operating Cash Flow | 500,000 |
| Capital Expenditures | -192.54M |
| Free Cash Flow | -20.44M |
| FCF Per Share | -$0.18 |
Full Cash Flow StatementMargins
Gross margin is 56.38%, with operating and profit margins of -26.45% and -48.09%.
| Gross Margin | 56.38% |
| Operating Margin | -26.45% |
| Pretax Margin | 18.05% |
| Profit Margin | -48.09% |
| EBITDA Margin | -24.58% |
| EBIT Margin | -26.45% |
| FCF Margin | n/a |